Abstract
INTRODUCTION
Protein drugs, as the name suggests, are pharmaceuticals based on proteins or
portions of proteins. Also referred to as biologics, protein drugs have become
increasingly important over the past 5 years with the advent of high
throughput screening and proteomics combined with the changing (some would say
declining) health status of the developed countries, particularly the United
States.
Technologies included in this report are: protein therapeutics, proteomics,
bioengineered protein drugs, recombinant protein drugs, protein arrays,
protein expression and protein purification, and protein chips.
Drugs included in this report are insulin, coagulants, interferons, cytokines,
bioengineered antibodies, enzymes, hormones (particularly growth hormones),
growth factors, interleukins and angiogenesis inhibitors.
Diseases for which protein drugs are particularly amenable and that will be
discussed in this report include: hemophilia, diabetes, cancer, cystic
fibrosis, hepatitis, psoriasis and congenital diseases.
SCOPE OF STUDY
This report contains:
- Coverage of proteins that are used for therapeutic purposes, including an
analysis of protein-based drugs in clinical trials
- Market trends and five-year forecasts with projections through 2011
- Examination of current technologies underlying the market and details the
effects of new technologies on this market
- Profiles of the major companies involved in the production and
modification of protein drugs.
- An analysis of the patent landscape in this field and the companies with
the greatest breadth in their IP portfolios.
METHODOLOGY AND SOURCES
This report uses a combination of direct and indirect sources. Direct sources
include interviews and conversations with scientists, analysts and research
consultants. Indirect sources include company news releases, governmental and
nongovernmental agencies, scientific journals and the popular press.
Sales were gathered from the most recently available data and represent
worldwide sales. In nearly all cases, this involved year-end 2005 sales. If
these figures were not available, then the latest available figures were used.
In some cases, data was not available. In these cases estimates were made
based on indirect data, such as patient populations, percentages treated with
other drugs and average sales prices.
Estimates for future sales growth within individual markets depended upon:
patent expirations, percentage of the market penetrated, generic competition,
competing drug classes, the introduction of new drugs, demographic growth and
shifts, recent study results, and other variables. In each case where a
forecast is made, the most important factors are listed.
Sales are presented in millions of dollars, unless otherwise noted.
ANALYST CREDENTIALS
Gargi Talukder has a doctorate in Neuroscience from Stanford University and a
law degree from the University of Chicago. She has over 10 years of experience
in the biotechnology sector.
| 
View Cart
